Innate Pharma : Des résultats T1 sans surprises dans l’attente de l’ASCO
>Visibilité financière jusqu’à fin 2025 - Innate Pharma publie ce matin sa topline et sa trésorerie au titre du premier trimestre 2024. La société ne réalise pas encore de CA récurrent, les revenus sur la période provenant essentiellement de reconnaissance de paiement reçus dans le cadre de ses partenariats avec AstraZeneca et Sanofi s’élèvent à 6.6 M€ (vs 26 M€ en 2023). La trésorerie à fin mars 2024 s’établit à 114 M€ contre 102.3 M€ fin décembre 2023 (sans tenir co...Innate Pharma S.A. is a biopharmaceutical Company developing immunotherapy drugs for cancer and inflammatory diseases. Co. specializes in the development of new monoclonal antibodies targeting receptors and pathways controlling the activation of innate immunity cells. Also, Co. has three product-candidates resulting from its research platform are being tested in clinical trials; two of these by Co.'s partners, Bristol-Myers Squibb and Novo Nordisk A/S. Co. focuses on immunopharmacology and antibody technology. Co. has a panel of molecular and cellular assays and in vivo models for assessing the pharmacodynamics, the pharmacotoxicology and efficacy of drug candidates.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.